Skip to content

Replimune Group REPL Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
0
GRAIL, Inc. logo
GRAIL, Inc.GRAL
0
Summit Therapeutics logo
Summit TherapeuticsSMMT
Incyte logo
IncyteINCY
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's convertible preferred stock issued shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's convertible preferred stock issued shares?
Replimune Group (REPL) reported convertible preferred stock issued shares of 0 in Q4 2025.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.